![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NTRK3 |
Gene summary for NTRK3 |
![]() |
Gene information | Species | Human | Gene symbol | NTRK3 | Gene ID | 4916 |
Gene name | neurotrophic receptor tyrosine kinase 3 | |
Gene Alias | GP145-TrkC | |
Cytomap | 15q25.3 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q96CY4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4916 | NTRK3 | PTC04 | Human | Thyroid | PTC | 2.66e-05 | 1.37e-01 | 0.1927 |
4916 | NTRK3 | ATC13 | Human | Thyroid | ATC | 5.36e-55 | 1.40e+00 | 0.34 |
4916 | NTRK3 | ATC5 | Human | Thyroid | ATC | 8.25e-73 | 1.46e+00 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0010563113 | Thyroid | PTC | negative regulation of phosphorus metabolic process | 219/5968 | 442/18723 | 4.47e-15 | 3.07e-13 | 219 |
GO:0045936113 | Thyroid | PTC | negative regulation of phosphate metabolic process | 218/5968 | 441/18723 | 7.08e-15 | 4.75e-13 | 218 |
GO:0032956113 | Thyroid | PTC | regulation of actin cytoskeleton organization | 182/5968 | 358/18723 | 4.64e-14 | 2.79e-12 | 182 |
GO:0032970113 | Thyroid | PTC | regulation of actin filament-based process | 197/5968 | 397/18723 | 8.91e-14 | 4.89e-12 | 197 |
GO:0001933113 | Thyroid | PTC | negative regulation of protein phosphorylation | 173/5968 | 342/18723 | 3.46e-13 | 1.75e-11 | 173 |
GO:0042326113 | Thyroid | PTC | negative regulation of phosphorylation | 189/5968 | 385/18723 | 1.00e-12 | 4.64e-11 | 189 |
GO:005149526 | Thyroid | PTC | positive regulation of cytoskeleton organization | 121/5968 | 226/18723 | 1.04e-11 | 4.27e-10 | 121 |
GO:0031346110 | Thyroid | PTC | positive regulation of cell projection organization | 173/5968 | 353/18723 | 1.09e-11 | 4.40e-10 | 173 |
GO:0048545113 | Thyroid | PTC | response to steroid hormone | 158/5968 | 339/18723 | 8.10e-09 | 2.00e-07 | 158 |
GO:0045860111 | Thyroid | PTC | positive regulation of protein kinase activity | 176/5968 | 386/18723 | 8.89e-09 | 2.17e-07 | 176 |
GO:0071900110 | Thyroid | PTC | regulation of protein serine/threonine kinase activity | 164/5968 | 359/18723 | 2.41e-08 | 5.43e-07 | 164 |
GO:0010975110 | Thyroid | PTC | regulation of neuron projection development | 194/5968 | 445/18723 | 1.05e-07 | 2.08e-06 | 194 |
GO:003153220 | Thyroid | PTC | actin cytoskeleton reorganization | 60/5968 | 107/18723 | 1.91e-07 | 3.51e-06 | 60 |
GO:0033674111 | Thyroid | PTC | positive regulation of kinase activity | 201/5968 | 467/18723 | 1.95e-07 | 3.54e-06 | 201 |
GO:001810518 | Thyroid | PTC | peptidyl-serine phosphorylation | 143/5968 | 315/18723 | 2.94e-07 | 5.04e-06 | 143 |
GO:001820916 | Thyroid | PTC | peptidyl-serine modification | 151/5968 | 338/18723 | 4.61e-07 | 7.51e-06 | 151 |
GO:0034329111 | Thyroid | PTC | cell junction assembly | 180/5968 | 420/18723 | 1.17e-06 | 1.69e-05 | 180 |
GO:005076716 | Thyroid | PTC | regulation of neurogenesis | 156/5968 | 364/18723 | 5.86e-06 | 7.05e-05 | 156 |
GO:190211516 | Thyroid | PTC | regulation of organelle assembly | 88/5968 | 186/18723 | 7.41e-06 | 8.65e-05 | 88 |
GO:007190210 | Thyroid | PTC | positive regulation of protein serine/threonine kinase activity | 93/5968 | 200/18723 | 1.01e-05 | 1.12e-04 | 93 |
Page: 1 2 3 4 5 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
NTF3 | NTRK3 | NTF3_NTRK3 | NT | Endometrium | ADJ |
NTF3 | NTRK3 | NTF3_NTRK3 | NT | Endometrium | AEH |
NTF3 | NTRK3 | NTF3_NTRK3 | NT | Liver | Healthy |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NTRK3 | SNV | Missense_Mutation | c.1150N>A | p.Leu384Met | p.L384M | Q16288 | protein_coding | deleterious(0.05) | benign(0.285) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
NTRK3 | SNV | Missense_Mutation | c.1426N>A | p.Asp476Asn | p.D476N | Q16288 | protein_coding | deleterious(0.04) | probably_damaging(0.937) | TCGA-EA-A3QE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
NTRK3 | SNV | Missense_Mutation | c.13N>G | p.Leu5Val | p.L5V | Q16288 | protein_coding | deleterious_low_confidence(0.05) | benign(0.026) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
NTRK3 | SNV | Missense_Mutation | rs546426782 | c.458N>A | p.Arg153Gln | p.R153Q | Q16288 | protein_coding | tolerated(0.5) | benign(0) | TCGA-MA-AA43-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
NTRK3 | SNV | Missense_Mutation | novel | c.486N>G | p.Phe162Leu | p.F162L | Q16288 | protein_coding | tolerated(1) | benign(0.023) | TCGA-ZJ-A8QR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
NTRK3 | SNV | Missense_Mutation | rs201426743 | c.947N>A | p.Arg316His | p.R316H | Q16288 | protein_coding | tolerated(0.65) | benign(0) | TCGA-AA-3664-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NTRK3 | SNV | Missense_Mutation | rs750055690 | c.1375C>T | p.Arg459Trp | p.R459W | Q16288 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-AA-3814-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NTRK3 | SNV | Missense_Mutation | novel | c.449T>C | p.Leu150Pro | p.L150P | Q16288 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NTRK3 | SNV | Missense_Mutation | c.56N>A | p.Gly19Glu | p.G19E | Q16288 | protein_coding | tolerated_low_confidence(0.28) | benign(0.071) | TCGA-AA-3833-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
NTRK3 | SNV | Missense_Mutation | rs546426782 | c.458N>A | p.Arg153Gln | p.R153Q | Q16288 | protein_coding | tolerated(0.5) | benign(0) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4916 | NTRK3 | CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOME | inhibitor | 381744997 | REPOTRECTINIB | |
4916 | NTRK3 | CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOME | inhibitor | 252827368 | PEXIDARTINIB | |
4916 | NTRK3 | CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOME | MK-2461 | MK-2461 | ||
4916 | NTRK3 | CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOME | Cyclopenta[d]pyrimidine derivative 1 | |||
4916 | NTRK3 | CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOME | SNS-314 | SNS-314 | ||
4916 | NTRK3 | CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOME | ILORASERTIB | ILORASERTIB | ||
4916 | NTRK3 | CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOME | SB-202190 | SB-202190 | ||
4916 | NTRK3 | CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOME | GW441756X | GW441756X | ||
4916 | NTRK3 | CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOME | IFN | 15875206 | ||
4916 | NTRK3 | CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOME | REPOTRECTINIB | REPOTRECTINIB | 30093503 |
Page: 1 2 3 4 5 6 7 |